Information Provided By: 
Fly News Breaks for November 16, 2016
MDCO
Nov 16, 2016 | 08:33 EDT
RBC Capital analyst Adnan Butt raised his price target on The Medicines Company after it reported Phase 2 data on its inclisiran drug that he views positively. The analyst says that the drug has differentiated efficacy and safety in LDL-C reduction. He thinks that safety questions created an overhang on the stock, but he still believes that the shares should have risen. The analyst believes that additional data due to be released by the company at the end of the year will be positive. He keeps an Outperform rating on the shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
